BMO Capital on Bristol-Myers Squibb Co. (BMY): 'likely down on sympathy at open but potentially overdone'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
